Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
Rheumatology (Oxford)
.
2018 Jun 1;57(6):1129.
doi: 10.1093/rheumatology/key116.
Authors
Ernest Choy
1
,
Roberto Caporali
2
,
Ricardo Xavier
3
,
Bruno Fautrel
4
,
Raimón Sanmarti
5
,
Min Bao
6
,
Corrado Bernasconi
7
,
Attila Pethö-Schramm
7
Affiliations
1
CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK.
2
Division of Rheumatology, University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
3
Department of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil.
4
Department of Rheumatology, APHP, Pitie Salpetriere Hospital, Pierre and Marie Curie University, Paris, France.
5
Department of Rheumatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
6
Genentech, South San Francisco, CA, USA.
7
F. Hoffmann-La Roche, Basel, Switzerland.
PMID:
29635639
PMCID:
PMC5965097
DOI:
10.1093/rheumatology/key116
No abstract available
Publication types
Published Erratum